Aura Biosciences, Inc.
Aura Biosciences (Nasdaq: AURA) is a clinical-stage biotechnology company developing precision therapies for solid tumors, with an initial focus on ocular and urologic cancers. Its lead candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate designed to target tumor cells and, when activated by… From the company’s description.
In fiscal 2025, Aura Biosciences, Inc. reported a net loss of $106.19M. Operations used $84.74M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Aura Biosciences, Inc. does
In the company’s own words
Aura Biosciences (Nasdaq: AURA) is a clinical-stage biotechnology company developing precision therapies for solid tumors, with an initial focus on ocular and urologic cancers. Its lead candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate designed to target tumor cells and, when activated by light, induce cell death and an immune response. Bel-sar is in a global Phase 3 trial for early choroidal melanoma and is also being studied for metastases to the choroid, cancers of the ocular surface, and non-muscle-invasive bladder cancer. The company’s development programs aim to treat tumors while preserving vision or organ function; it has not yet commercialized a pharmaceutical product. Its research and development pipeline centers on bel-sar, which combines modified human papillomavirus capsid proteins with light-activated molecules. Aura Biosciences was developing this candidate across several clinical indications as of fiscal 2025. Its website is https://aurabiosciences.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BOSTON, MA
- Fiscal year end
- December
- CIK
- 1501796
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Aura Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Aura Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Aura Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Aura Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Aura Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”